

# Institut für Lungenforschung und pneumologische Onkologie

Institutsleitung: Prim. Priv.-Doz. Dr. Arschang Valipour

## Wissenschaftliche Referate 2022:

- **46. Jahrestagung der Österreichischen Gesellschaft für Pneumologie 29.9. – 1.10.2022** (Maximilian Hochmair, Michael Meilinger, Erwin Grasmuk-Siegl, Matthias Urban, Arschang Valipour)
- **12. Bronchuskarzinom-Workshop 25. – 26.11.2022** (Maximilian Hochmair, Michael Meilinger, Irina Robinson)
- **9. Pneumo Aktuell 29.01.2022** (Maximilian Hochmair)
- **Weiterbildung Onkologische Pflege: "Tumorerkrankungen des Thorax" 13.09.2021** (Oliver Illini)
- **World Conference on Lung Cancer 2022: „Intensive Care for Lung Cancer Patients“** (Erwin Grasmuk-Siegl)
- **Nicht zaudern, sondern rasch verschreiben! Update: Orale COVID-19 Therapie 22. August 2022** (Arschang Valipour)
- **Pulmosolutions for peripheral lung biopsy: From screening to treatment planning 16.11.2022** (Arschang Valipour)
- **"Innovativ. Zielgerichtet. Personalisiert: Modernes Therapiemanagement des Lungenkarzinoms" – Pressekonferenz 25.10.2022** (Maximilian Hochmair)
- **Medizin To Go Podcast: „Asthma – Ist alles unter Kontrolle?“ & „Idiopathische Lungenfibrose - Wenn die Lunge knistert“** (Arschang Valipour)
- **Wissenschaft und Forschung: "Long-COVID" 01.03.2022** (Arschang Valipour)

## Wissenschaftliche Publikationen 2022:

- **UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-Line Setting (UNICORN).**  
Bar J, Peled N, Schokrpur S, Wolner M, Rotem O, Girard N, Aboubakar Nana F, Derijcke S, Kian W, Patel S, Gantz-Sorotsky H, Zer A, Moskovitz M, Metro G, Rottenberg Y, Calles A, **Hochmair M**, Cuppens K, Decoster L, Reck M, Limon D, Rodriguez E, Astaras C, Bettini A, Häfliger S, Addeo A.  
J Thorac Oncol. 2022 Oct 25:S1556-0864(22)01854-8. doi: 10.1016/j.jtho.2022.10.004

- Brief Report: Exploratory Analysis of Maintenance Therapy in Patients With Extensive-Stage SCLC Treated First Line With Atezolizumab Plus Carboplatin and Etoposide.**  
 Reck M, Mok TSK, Mansfield A, De Boer R, Losonczy G, Sugawara S, Dziadziuszko R, Krzakowski M, Smolin A, **Hochmair M**, Garassino MC, de Castro Junior G, Bischoff H, Lam S, Cardona A, Morris S, Liu SV.  
 J Thorac Oncol. 2022 Sep;17(9):1122-1129. doi: 10.1016/j.jtho.2022.05.016.
- Impaired Spontaneous Baroreceptor Reflex Sensitivity in Patients With COPD Compared to Healthy Controls: The Role of Lung Hyperinflation.**  
**Mayr AK**, Wieser V, Funk GC, Asadi S, Sperk I, **Urban MH**, **Valipour A**.  
 Front Med (Lausanne). 2022 Jan 3;8:791410. doi: 10.3389/fmed.2021.791410
- Effect of short-term storage of blood samples on gene expression in lung cancer patients.**  
 Obermayr E, Koppensteiner N, Heinzl N, Schuster E, Holzer B, **Fabikan H**, **Weinlinger C**, **Illini O**, **Hochmair MJ**, Zeillinger R Clin Chem Lab Med. 2022 Nov 17;61(2):294-301. doi: 10.1515/cclm-2022-0738.
- Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.**  
 Paz-Ares L, Chen Y, Reinmuth N, Hotta K, Trukhin D, Statsenko G, **Hochmair MJ**, Özgüroğlu M, Ji JH, Garassino MC, Voitko O, Poltoratskiy A, Musso E, Havel L, Bondarenko I, Losonczy G, Conev N, Mann H, Dalvi TB, Jiang H, Goldman JW.  
 ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408.
- Multimodal Treatment of Malignant Pleural Mesothelioma: Real-World Experience with 112 Patients.**  
 Holzknacht A, **Illini O**, **Hochmair MJ**, Krenbek D, Setinek U, Huemer F, Bitterlich E, Kaindl C, Getman V, Akan A, Weber M, Leobacher G, **Valipour A**, Mueller MR, Watzka SB.  
 Cancers (Basel). 2022 Apr 30;14(9):2245. doi: 10.3390/cancers14092245.
- Durvalumab after Sequential High Dose Chemoradiotherapy versus Standard of Care (SoC) for Stage III NSCLC: A Bi-Centric Trospective Comparison Focusing on Pulmonary Toxicity.**  
 Wass R, **Hochmair M**, Kaiser B, Grambozov B, Feurstein P, Weiß G, Moosbrugger R, Sedlmayer F, Lamprecht B, Studnicka M, Zehentmayr F.  
 Cancers (Basel). 2022 Jun 30;14(13):3226. doi: 10.3390/cancers14133226.
- Effectiveness of Outpatient Pulmonary Rehabilitation in Patients with Surgically Resected Lung Cancer: A Retrospective Real-World Analysis.**  
**Illini O**, **Valipour A**, Gattinger D, Petrovic M, **Fabikan H**, **Hochmair MJ**, Zwick RH.  
 Cancers (Basel). 2022 Jul 18;14(14):3479. doi: 10.3390/cancers14143479.
- Real-world experience with capmatinib in MET exon 14-mutated non-small cell lung cancer (RECAP): a retrospective analysis from an early access program.**  
**Illini O**, **Fabikan H**, Swalduz A, Vikström A, Krenbek D, Schumacher M, Dudnik E, Studnicka M, Öhman R, Wurm R, Wannesson L, Peled N, Kian W, Bar J, Daher S, Addeo A, Rotem O, Pall G, Zer A, Saad A, Cufer T, Sorotsky HG, Hashemi SMS, Mohorcic K, Stoff R, Rovitsky Y, Keren-Rosenberg S, Winder T, **Weinlinger C**, **Valipour A**, **Hochmair MJ**.  
 Ther Adv Med Oncol. 2022 Jun 13;14:17588359221103206. doi: 10.1177/17588359221103206.

- **Characteristics and Treatment Outcomes in Advanced-Stage Non-Small Cell Lung Cancer Patients with a KRAS G12C Mutation: A Real-World Study.**  
 Illini O, Fabikan H, Hochmair MJ, Weinlinger C, Krenbek D, Brcic L, Setinek U, Terbuch A, Absenger G, Konjić S, Valipour A.  
 J Clin Med. 2022 Jul 15;11(14):4098. doi: 10.3390/jcm11144098.
- **Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study.**  
 Ahn MJ, Kim HR, Yang JCH, Han JY, Li JY, Hochmair MJ, Chang GC, Delmonte A, Lee KH, Campelo RG, Gridelli C, Spira AI, Califano R, Griesinger F, Ghosh S, Felip E, Kim DW, Liu Y, Zhang P, Popat S, Camidge DR.  
 Clin Lung Cancer. 2022 Dec;23(8):720-730. doi: 10.1016/j.clcc.2022.07.008.
- **Cytotoxicity of combinations of the pan-KRAS SOS1 inhibitor BAY-293 against pancreatic cancer cell lines.**  
 Plangger A, Rath B, Stickler S, Hochmair M, Lang C, Weigl L, Funovics M, Hamilton G.  
 Discov Oncol. 2022 Sep 1;13(1):84. doi: 10.1007/s12672-022-00550-w.
- **A multicenter, prospective, single-arm clinical investigation of a modified staged treatment algorithm using the AeriSeal system - The STAGE trial.**  
 Koster TD, Eberhardt R, Huebner RH, Valipour A, Herth F, Klooster K, Shargill NS, Radhakrishnan S, Slebos DJ.  
 Respir Med. 2022 Nov;203:106989. doi: 10.1016/j.rmed.2022.106989.
- **Computed tomographic airway morphology after targeted lung denervation treatment in COPD.**  
 Hartman JE, Herth FJF, Shah P, Pison C, Valipour A, Slebos DJ; AIRFLOW-2 Study Group.  
 Respir Med. 2023 Jan;206:107059. doi: 10.1016/j.rmed.2022.107059.
- **Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies.**  
 Miura S, Jung HA, Lee SY, Lee SH, Lee MK, Lee YC, Hochmair MJ, Yang CT, Märten A, Yang JC, Popat S.  
 Onco Targets Ther. 2022 Aug 22;15:873-882. doi: 10.2147/OTT.S362535.
- **Recommendations for COPD management in Central and Eastern Europe.**  
 Valipour A, Aisanov Z, Avdeev S, Koblizek V, Kocan I, Kopitovic I, Lupkovics G, Man M, Bukovskis M, Tudoric N, Vukoja M, Naumnik W, Yanev N.  
 Expert Rev Respir Med. 2022 Feb;16(2):221-234. doi: 10.1080/17476348.2021.2023498.
- **Bronchoscopic Lung Volume Reduction Coil Treatment for Severe Emphysema: A Systematic Review and Meta-Analysis of Individual Participant Data.**  
 Roodenburg SA, Hartman JE, Deslée G, Herth FJF, Klooster K, Sciruba FC, Shah PL, Valipour A, Zoumot Z, Slebos DJ.  
 Respiration. 2022;101(7):697-705. doi: 10.1159/000524148.

- **Crossover Patient Outcomes for Targeted Lung Denervation in Moderate to Severe Chronic Obstructive Pulmonary Disease: AIRFLOW-2.**  
 Conway F, Tonkin J, **Valipour A**, Pison C, Schumann C, Bonta PI, Kessler R, Gesierich W, Darwiche K, Lamprecht B, Skowasch D, Johnson PJ, Slebos DJ, Shah PL; AIRFLOW-2 Trial Study Group.  
 Respiration. 2022;101(11):1069-1074. doi: 10.1159/000527455
- **Management of patients with SARS-CoV-2 infections with focus on patients with chronic lung diseases (as of 10 January 2022) : Updated statement of the Austrian Society of Pneumology (ASP).**  
 Olschewski H, Eber E, Bucher B, Hackner K, Handzhiev S, Hoetzenecker K, Idzko M, Klepetko W, Kovacs G, Lamprecht B, Löffler-Ragg J, **Meilinger M**, Müller A, Prior C, Schindler O, Täubl H, Zacharasiewicz A, Zwick RH, Arns BM, Bolitschek J, Cima K, Gingrich E, **Hochmair M**, Horak F, Jaksch P, Kropfmüller R, Pflieger A, Puchner B, Puelacher C, Rodriguez P, Salzer HJF, Schenk P, Stelzmüller I, Strenger V, **Urban M**, Wagner M, Wimberger F, Flick H.  
 Wien Klin Wochenschr. 2022 May;134(9-10):399-419. doi: 10.1007/s00508-022-02018-x
- **Effect of intravenous ferric carboxymaltose on exercise capacity and quality of life in patients with COPD : A pilot study.**  
**Grasmuk-Siegl E, Urban MH**, Scherrer S, Funk GC.  
 Wien Klin Wochenschr. 2022 Aug 31. doi: 10.1007/s00508-022-02073-4
- **Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials.**  
 Gettinger SN, Huber RM, Kim DW, Bazhenova L, Hansen KH, Tiseo M, Langer CJ, Paz-Ares Rodríguez LG, West HL, Reckamp KL, Weiss GJ, Smit EF, **Hochmair MJ**, Kim SW, Ahn MJ, Kim ES, Groen HJM, Pye J, Liu Y, Zhang P, Vranceanu F, Camidge DR.  
 JTO Clin Res Rep. 2022 Jul 31;3(9):100385. doi: 10.1016/j.jtocrr.2022.100385.
- **Therapeutic Success in Swiss COPD Patients Receiving Dual Bronchodilation Therapy as COPD Maintenance Treatment.**  
 Spielmanns M, Schildge S, Diedrich JP, **Valipour A**.  
 Clin Pract. 2022 Jan 7;12(1):46-56. doi: 10.3390/clinpract12010006.
- **Nintedanib plus Docetaxel after Immune Checkpoint Inhibitor Failure in Patients with Advanced Non-Small-Cell Lung Cancer: A Case Series.**  
**Hochmair MJ**, Kolb R, Wurm R, Zach H, Bittner N.  
 Case Rep Oncol. 2022 Feb 14;15(1):138-148. doi: 10.1159/000520939
- **Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report.**  
 Chen Y, Paz-Ares L, Reinmuth N, Garassino MC, Statsenko G, **Hochmair MJ**, Özgüroğlu M, Verderame F, Havel L, Losonczy G, Conev NV, Hotta K, Ji JH, Spencer S, Dalvi T, Jiang H, Goldman JW.  
 JTO Clin Res Rep. 2022 Apr 26;3(6):100330. doi: 10.1016/j.jtocrr.2022.100330
- **Treatment of persistent COVID-19 in two B-cell-depleted patients with the monoclonal antibody Sotrovimab.**  
 Totschnig D, Doberer D, Haberl R, Wenisch C, **Valipour A**.  
 IDCases. 2022;29:e01528. doi: 10.1016/j.idcr.2022.e01528